RT Journal Article
SR Electronic
T1 Treatment and survival diversities in different forms of ILD in Germany - EXCITING registry
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA4725
DO 10.1183/13993003.congress-2019.PA4725
VO 54
IS suppl 63
A1 Michael Kreuter
A1 Hans-Joachim Kabitz
A1 Lars Hagmeyer
A1 Peter Hammerl
A1 Albert Esselmann
A1 Conrad Wiederhold
A1 Dirk Skowasch
A1 Christoph Stolpe
A1 Marcus Joest
A1 Stefan Veitshans
A1 Phillen Maqhuzu
A1 Larissa Schwarzkopf
A1 Andreas Hellmann
A1 Michael Pfeifer
A1 Jürgen Behr
A1 Dagmar Kauschka
A1 Andreas Günther
A1 Felix J. F. Herth
A1 Philipp Markart
YR 2019
UL http://erj.ersjournals.com/content/54/suppl_63/PA4725.abstract
AB Background: Real life data on outcome and treatment diversities in different ILD are scant.Method: We analysed prospective data from the German EXCITING registry of consecutive ILD patients in 37 pulmonology centres.Results: Out of 601 patients (60% male, medians: age 64 years, FVC 75%, DLCO 53%), 40% had idiopathic forms (IIP), 28% sarcoidosis, 10% hypersensitivity pneumonitis (HP) and 7% CTD-ILD. At baseline, IIPs were mainly treated with antifibrotic drugs (66%), but also received prednisolone in 49%. Sarcoidosis, HP and CTD-ILD mainly received steroids (85%, 98% and 81%) and rarely other immunosuppressants (azathioprine 12%, 27%, 34%; MTX 15%, 9%, 9%). Non-pharmacological treatments were sparse and did not increase over time: pulmonary rehabilitation at baseline (base) and during follow up (FU) 4%, LTOT at base 18%, increase to 21%, and NIV 4% at base and during FU. Only 3 patients received LTX. At base, 48% (n=288) were hospitalised, in 94% due to ILD, mainly for diagnostic procedures (72%) and rarely for other reasons (pneumonia 12%, AE-ILD 16%). After 6 and 12 months, hospitalisations decreased (n=127) with less frequent ILD association (72% after 6, 42% after 12 months). Yet, non-elective hospitalisations increased (at 6 and 12 months: infections 33% and 30%, AE-ILD 15% and 23%) over time. Mean overall survival by Kaplan-Meier estimates (total cohort 168 months (± 6)) differed in patients between IIP, sarcoidosis and HP with 107 months (±7), 225 (± 6.8), and 166 months (± 18).Conclusions: ILDs differ substantial in treatment forms and outcomes. Notably, non-pharmacological treatments are mainly neglected and despite a high rate of severe ILDs only 3 LTX were performed.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA4725.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).